Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-2.97%+14.99%-8.68% 67.46B
-1.32%-8.39%+34.74%+193.12% 51.13B
-2.29%+36.80%+36.80%+36.80% 43.4B
-0.97%-2.11%-51.46%-52.99% 40.32B
-8.17%-6.68%+44.20%-31.18% 30.86B
+0.64%-15.46%+105.17%-44.43% 26.59B
+0.57%-2.69%+64.16%+86.01% 22.82B
+8.83%+13.34%+13.74%+210.16% 19.79B
-1.56%-5.38%+53.69%+123.21% 16.47B
Average -0.64%-4.68%+35.12%+56.89% 35.43B
Weighted average by Cap. -1.13%-4.54%+28.51%+46.28%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-